Re-evaluating Radioresistance in Soft Tissue Sarcoma - Live

May 5, 2026

Webinar Information

Webinar Description

Ted K. Yanagihara, MD, PhD, will review the long-standing dogma that sarcoma represents a radioresistant histology and challenge this notion through a more nuanced, biology-driven lens. By distinguishing intrinsic radiosensitivity from observed clinical radioresponsiveness, we will explore how factors such as dose, fractionation, tumor microenvironment, and histologic subtype shape outcomes. We will also discuss emerging clinical trial data that are reshaping sarcoma management—including the growing integration of systemic therapies—and highlight ongoing clinical trials at our institution.

Learning Objectives

  • Distinguish between radiosensitivity and radioresponsiveness, and explain how intrinsic tumor biology and extrinsic treatment factors contribute to the concept of radioresistance.
  • Describe the biological and microenvironmental factors (e.g., DNA repair capacity, hypoxia, tumor heterogeneity, and stem cel lpopulations) that influence radiation response across sarcoma subtypes.
  • Interpret recent clinical trial data and emerging treatment paradigms—including integration of systemic therapy—and evaluate how these insights inform contemporary, multidisciplinary management of sarcoma patients.

 

Webinar Documents

Flyers

Feel free to share the flyer and/or this webpage.

Poll Everywhere Link

Please give poll responses via web at:

 

Webinar Registration


Take Course

You must have an account and be logged in to register for and to access the course.

Please contact us with any questions at [email protected] or (919) 445–1000.

The views expressed herein are those of the presenter, they do not necessarily reflect the views of the contracted organization, department, School of Medicine, nor the University of North Carolina at Chapel Hill.

 


Course summary
Available credit: 
  • 1.00 ABIM Medical Knowledge
  • 1.00 AMA PRA Category 1 Credit™
Course opens: 
01/16/2026
Course expires: 
05/12/2026
Event starts: 
05/05/2026 - 4:00pm EDT
Event ends: 
05/05/2026 - 5:00pm EDT
Add to calendar: 
Cancer Grand Rounds Logo 

The Lineberger Cancer Center Grand Rounds are educational activities regarding cancer. We cover the most relevant oncology topics.

These webinars provide FREE continuing education credit.

UNC Lineberger Cancer Grand Rounds are presented as a hybrid event with in-person and online viewing options. 

Image of peopleORImage of webinar icon
In-person at:
Conference Room 1 at the N.C. Basnight Cancer Hospital		 


Online via Zoom:
Link will be provided in confirmation email

 

Photo of Theodore (Ted) Yanagihara, MD, PhD 

Theodore (Ted) Yanagihara, MD, PhD

Assistant Professor
Department of Radiation Oncology
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Disclosures

Activity Planners
This activity has been planned and implemented under the sole supervision of the Course Directors, Jared Weiss, MD; Deborah Marie Stephens, DO; and Kaitlin Morrison, PhD, of the UNC School of Medicine in association with the UNC Office of Continuing Professional Development (CPD). Dr. Weiss is a stockholder in Vesselon, Nuvalent, En Fuego Therapeutics, Vertex, Merus, Revmed; receives consulting fees from AZ, EMD Serono, Nanobiotix, PDS, Amgen, Pharmacosmos, GSK; and receives research grants from Pharmacosmos, Loxo, PDS, Genmab, Iovance, Nurix, TSCAN, Janus, BMS, Summit. These financial relationships have been mitigated. Dr. Stephens has served on advisory boards for Abbvie, AstraZeneca, BeOne, BMS, Genentech, Pfizer, Pharmacyclics, J&J. These were one time consulting efforts, but she is asked periodically to serve on additional boards. She is a consultant for Abbvie and this is an ongoing relationship. She has also received research grants research grants to Lineberger Comprehensive Cancer Center from BeOne, which are ongoing. Dr. Morrison has no relevant financial relationships with ineligible companies as defined by the ACCME. CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME. The planning committee members and their relevant financial relationships with ineligible companies as defined by the ACCME can be found at https://learn.unclcn.org/content/lineberger-cancer-center-grand-rounds-planning-committee.

Speaker
The presenter has no relevant financial relationships with ineligible companies as defined by the ACCME.

 

Accreditation Statements

1.00 ABIM MOC Part 2 Credit
CME MOC ABIM badge
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Part 2 credit.

1.00 AMA PRA Category 1 Credit™
The School of Medicine of The University of North Carolina at Chapel Hill designates this activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The School of Medicine of the University of North Carolina at Chapel Hill designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Notice

Attendees are required to view a minimum of 53 minutes of the live webinar video to receive CME credit.

Available Credit

  • 1.00 ABIM Medical Knowledge
  • 1.00 AMA PRA Category 1 Credit™
Please login or register to take this course.